HHS Files Enforcement Discretion Policy for 503A Peptide Compounding

On October 28, 2026, the Department of Health and Human Services (HHS) filed a Federal Register notice — FR Doc. 2026-22192, Docket HHS-OASH-2026-0496, RIN 0910-ZD94 — titled "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." The notice is scheduled for publication in the Federal Register on October 30, 2026.

The notice announces the availability of a draft enforcement discretion policy describing HHS's position on the use of certain peptide bulk drug substances in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) while the official list of bulk drug substances that can be used in 503A compounding — known as the 503A bulks list — is developed through rulemaking.

Key point: HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A of the policy document.

The peptides covered are listed in Appendix A; secondary reporting indicates the six peptides are BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500.

This is a notice of availability of a draft policy — it is not binding regulation, and it is not FDA approval of any peptide. HHS may revisit the policy if a safety signal or product quality issue arises.

Understanding this announcement requires context on three regulatory terms:

503A Compounding

Section 503A of the FD&C Act (21 U. S. C. § 353a) describes the conditions under which traditional compounding by state-licensed pharmacies, federal facilities, and licensed physicians can occur.

503A compounding is for patient-specific prescriptions, typically in lower volumes than large-scale manufacturing.

Compounders operating under 503A are generally not required to register as drug manufacturers and do not need to comply with current Good Manufacturing Practice (cGMP) regulations, provided they meet the conditions in 503A.

503A Bulks List (21 CFR 216.23)

Under section 503A, a bulk drug substance can be used in compounding if it is a component of an FDA-approved drug, has a USP or NF monograph, or appears on the 503A bulks list established through rulemaking by the FDA (per Holland & Knight legal analysis).

Peptides not meeting these criteria are generally not permitted for 503A compounding — unless a specific enforcement discretion applies.

Enforcement Discretion

Enforcement discretion is a policy statement indicating that the agency does not currently intend to take enforcement action against certain activities, even if those activities might otherwise violate the law.

It is not a legal authorization, not a formal approval, and not binding on the agency. The agency can revoke or modify the policy at any time, particularly if safety or quality concerns arise.

Category 2 and PCAC Context

Prior to this announcement, several of the peptides in question — including BPC-157 and TB-500 — had been nominated for inclusion on the 503A bulks list, then had those nominations withdrawn, and were discussed at July 2026 Pharmacy Compounding Advisory Committee (PCAC) meetings.

The PCAC is an advisory body; its recommendations are non-binding. As of October 2026, FDA has not finalized rulemaking adding these peptides to the 503A bulks list (21 CFR 216.23).

The HHS enforcement discretion policy is an interim measure while rulemaking proceeds.

The October 28 Federal Register notice is the latest step in a multi-year regulatory process. Understanding the timeline helps researchers and procurement teams orient this policy within the broader peptide regulatory landscape:

Date	Event
April 15, 2026	FDA announced removal of 12 peptides from Category 2 after nominations were withdrawn, and published a Federal Register notice scheduling advisory committee review (per Holland & Knight)
June 29, 2026	FDA staff briefing materials recommended against adding any of the seven peptides under review (per Holland & Knight)
July 23–24, 2026	PCAC meeting: committee voted to recommend six peptides for inclusion (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax — BPC-157, KPV, and TB-500 each 8-6 with one abstention; per Holland & Knight) and voted against emideltide (DSIP, 6-7 with one abstention)
October 14, 2026	Interim access policy sent to OMB/OIRA for review (RIN 0910-ZD94; received by OIRA 10/14/2026; review concluded 10/27/2026, "Consistent with Change"; reginfo.gov)
October 28, 2026	HHS filed Federal Register notice (FR Doc. 2026-22192) announcing enforcement discretion policy
October 30, 2026 (scheduled)	Federal Register publication; public comment window opens for 2 weeks on regulations.gov docket HHS-OASH-2026-0496
Before end of Feb 2027	Second PCAC meeting expected before end of February 2027 for the remaining five peptides removed from Category 2 (GHK-Cu, LL-37, Dihexa, Melanotan II, PEG-MGF), with no date set yet (per Holland & Knight)

Sources: Federal Register notice FR Doc. 2026-22192; Holland & Knight legal analysis (hklaw.com insights Oct 16, 2026); NBC News health reporting (nbcnews.com Oct 28, 2026); The Hill (Oct 28, 2026).

The Federal Register notice refers to Appendix A of the HHS enforcement discretion policy document, hosted at hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf; we could not retrieve the HHS PDF at time of writing.

NBC News and The Hill (Oct 28, 2026) report the six are:

• BPC-157
• Epitalon
• KPV
• MOTS-c
• Semax
• TB-500

None of these peptides are FDA-approved drugs. The FDA said pharmacies must certify identity and purity and report side effects (per NBC News).

Important: We have not independently verified the full text of the Appendix A policy document or the specific conditions imposed. Pharmacies, federal facilities, and physicians should obtain the policy document from HHS and consult qualified regulatory counsel before relying on this enforcement discretion.

See our compound research pages for context on these peptides:

• BPC-157 research page
• TB-500 research page
• DSIP (emideltide) research page

We do not currently maintain dedicated research pages for epitalon, KPV, MOTS-c, or semax; those may be added based on research interest and RUO catalog availability.

The notice is limited to 503A compounders (state-licensed pharmacies, federal facilities and licensed physicians); Holland & Knight notes it does not extend to research-use-only, dietary supplement or 503B outsourcing channels. Understanding what it does and does not cover is critical for laboratories, researchers, and procurement teams:

What the policy covers	What it does NOT cover
State-licensed pharmacies compounding under 503A	Research-use-only (RUO) catalog suppliers
Federal facility compounding	Dietary supplement channels
Licensed physicians compounding	503B outsourcing facilities (large-scale compounding)
Peptides listed in Appendix A (six peptides per NBC News and The Hill)	Other peptides not in Appendix A
Compounding for patient-specific prescriptions	Commercial sale or distribution without prescription
Interim period while 503A bulks list rulemaking proceeds	Permanent authorization or FDA approval

Critical distinction for researchers: This enforcement discretion policy applies to 503A compounding pharmacies, federal facilities, and licensed physicians. It does not apply to RUO catalog suppliers selling peptides for laboratory and analytical use. RUO vendors operate under different regulatory frameworks (research chemical commerce, not pharmacy compounding) and are not covered by this policy.

According to Holland & Knight legal analysis, FDA has stepped up enforcement against RUO sellers since August 2026. Researchers sourcing peptides for non-clinical laboratory use should ensure suppliers maintain clear RUO positioning, batch-specific COA documentation, and institutional customer focus. See our RUO documentation checklist for procurement best practices.

This enforcement discretion policy is an interim measure. Several next steps will shape the long-term regulatory landscape for peptide compounding and research sourcing:

October 30, 2026: Federal Register Publication and Comment Window

The notice is scheduled for publication in the Federal Register on October 30, 2026. From that date, the public has 2 weeks to submit comments via regulations.gov docket HHS-OASH-2026-0496. Comments can address the policy scope, the peptides covered, the conditions imposed, or any other aspect of the draft policy.

Ongoing: 503A Bulks List Rulemaking

Formal rulemaking to add these peptides to the 503A bulks list has not begun (per Holland & Knight, Oct 16, 2026).

FDA may propose adding some or all of the peptides covered by this enforcement discretion to the official bulks list through notice-and-comment rulemaking, based on the available evidence.

Until that rulemaking is complete, the enforcement discretion policy is the operative framework for the six covered peptides.

Before End of February 2027: Second PCAC Meeting

According to Holland & Knight, a second PCAC meeting is expected before the end of February 2027 to review additional peptides: GHK-Cu, LL-37, Dihexa, Melanotan II, and PEG-MGF. PCAC recommendations are advisory and non-binding, but they inform FDA rulemaking.

Watch for Safety Signals or Quality Issues

The Federal Register notice explicitly states that HHS may revisit the enforcement discretion policy — in whole or in part — if a safety signal or product quality issue arises with a compounded drug product within the scope of the policy.

Adverse event reporting and product quality surveillance will be important factors in whether this policy remains in place or is modified.

Monitor FDA.gov and Regulations.gov

Official updates will appear on FDA.gov, in Federal Register notices, and in the regulations.gov docket HHS-OASH-2026-0496. Secondary reporting from legal firms and news outlets is useful for initial awareness, but procurement teams and institutional counsel should verify all facts against primary federal sources.

We will update our regulatory timeline and FDA reclassification analysis as new information becomes available.

Does this enforcement discretion policy affect RUO peptide orders?

No. The policy applies to 503A compounding pharmacies, federal facilities, and licensed physicians. It does not apply to RUO catalog suppliers selling peptides for laboratory and analytical use. Researchers purchasing peptides for non-clinical laboratory protocols should continue to follow institutional procurement policies and ensure suppliers maintain clear RUO positioning and batch-specific COA documentation.

Is this the same as FDA approval?

No. Enforcement discretion is not FDA approval, not a formal authorization, and not binding. It is a policy statement indicating that HHS does not currently intend to take enforcement action under certain conditions. The peptides covered remain unapproved drug products, and compounding with them does not constitute FDA approval.

Does this add these peptides to the 503A bulks list?

No. The peptides are not added to 21 CFR 216.23 (the official 503A bulks list) by this enforcement discretion policy. The policy is an interim measure while rulemaking proceeds. FDA may propose adding some or all of these peptides to the bulks list through formal rulemaking, but that has not occurred as of October 28, 2026.

Where can I read the full policy document?

The HHS enforcement discretion policy document is hosted at hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf. The Federal Register notice (FR Doc. 2026-22192) will be published October 30, 2026 at federalregister.gov and govinfo.gov. The public inspection page is at federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances.

What should I do if I source peptides for laboratory research?

Continue to follow your institution's procurement policies. Ensure suppliers provide batch-specific third-party COAs, maintain RUO labeling, and do not make therapeutic claims. Maintain protocol records, purchase approvals, and storage logs. See our RUO documentation checklist and COA literacy guide.